Amgen stock (US0311621009): Q1 earnings beat with revenue up 5.8%

Amgen released its Q1 2026 earnings on April 30, 2026, reporting revenue of $8.62 billion, a 5.8% increase from the prior year and 0.5% above consensus estimates of $8.58 billion, Ad-hoc-news.de as of May 12, 2026. Adjusted EPS reached $5.15, surpassing expectations of $4.77. The company maintained full-year revenue guidance at $21.70-$23.10 billion amid robust demand in biotechnology.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Amgen Inc.: core business model

Amgen Inc. develops and markets human therapeutics based on cellular and molecular biology for serious illnesses including cancer, inflammation, bone disease, and cardiovascular conditions. The company focuses on biologics, particularly monoclonal antibodies and other protein-based therapies. Its portfolio includes blockbuster drugs like Enbrel for rheumatoid arthritis, Prolia for osteoporosis, and Repatha for cholesterol reduction. Amgen operates globally with a strong emphasis on innovation through R&D investment.

Main revenue and product drivers for Amgen Inc.

Key products drove Q1 2026 performance, with oncology drugs such as Kyprolis and Blincyto contributing significantly. Revenue growth reflected sustained demand for established franchises amid patent protections. The company reported $8.62 billion in total revenue for the quarter ended March 31, 2026, published April 30, 2026. Full-year guidance underscores confidence in core portfolio stability and pipeline advancements.

Industry trends and competitive position

The biotechnology sector faces biosimilar competition and pricing pressures, yet Amgen maintains leadership through diversified revenue streams. US market exposure remains critical for investors, as Medicare and commercial reimbursement influence sales. Amgen's scale enables robust R&D spending, positioning it against rivals like AbbVie and Regeneron.

Why Amgen Inc. matters for US investors

Listed on Nasdaq, Amgen offers US investors direct access to a biotech leader with substantial domestic revenue from oncology and rare disease treatments. Its products address high-prevalence conditions in the aging US population, tying performance to healthcare spending trends.

Conclusion

Amgen's Q1 2026 results highlight resilient revenue growth and earnings beats, supporting full-year outlook. Recent share price activity, including a decline to $331.57 on May 13, 2026 amid analyst adjustments, reflects market dynamics. Investors track pipeline progress and competitive pressures in biotech.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.